

REMARKS

Claims 25-31 and 33-48 are currently pending in this application. Claims 25-29 are withdrawn from consideration, and claims 30, 31, and 33-48 are rejected. Claims 30, 44, and 45 are amended herein.

Rejections under 35 U.S.C. 112

Claims 30, 31, and 33-48 are rejected under 35 U.S.C. § 112, first paragraph because “the specification, while being enabling for compounds that inhibit a narrow range of mycobacterium including *tuberculosis*, *bovis* and *avium-intracellulare*, does not reasonably provide enablement for the treatment of ‘any’ mycobacterial infection using the full scope of the claimed compounds.” Final Office Action at 3. Applicants respectfully traverse this rejection.

Applicants have amended claims 30, 44, and 45 to claim methods of treating an animal with a *pathogenic* mycobacterial infection. Applicants submit that no new matter is introduced by the this amendment because support for the amended claims can be found in the specification at least at page 1, lines 8-9, which discloses, “the use of these compounds to treat any susceptible pathogenic microorganism or parasite.” Moreover, the specification would have enabled those of skill in the art to use of the compounds of formula I to treat pathogenic mycobacterial infections without undue experimentation. *See* Declaration of J. Dick. Accordingly, Applicants respectfully request that this rejection be withdrawn.